Discover how the FIT test is transforming colorectal cancer screening, reducing mortality rates and offering a more ...

Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and ...

Fecal Immunochemical Diagnostic Test (FIT) Market The FIT market is growing due to increased awareness and adoption of non-invasive colorectal cancer screening options. WILMINGTON, DE, UNITED STATES,.

DiaCarta Inc., a precision molecular diagnostic company, has announced the publication of its prospective clinical trial data on its blood-based test for triaging FIT (fecal immunochemical ...

Under the agreement, Sysmex will distribute and service in Canada Sentinel Diagnostics' SentiFit 270 and SentiFit 800 analyzers for fecal immunochemical testing.

Faecal immunochemical test (FIT) has been reported to outperform guaiac faecal occult blood tests ... although the screening modality in their study consisted of guaiac fecal occult blood test (gFOBT) ...

In New York, colorectal cancer is a top cause of cancer deaths across all populations. While screening rates have improved, ...

A1, a new biomarker, improves early detection of colorectal cancer with higher accuracy and less invasiveness.

Jochim S Terhaar sive Droste; Sietze T van Turenhout; Frank A Oort; René WM van der Hulst; Vincent A Steeman; Usha Coblijn; Lisette van der Eem; Ruud Duijkers; Anneke A Bouman; Gerrit A Meijer ...

Stool DNA (sDNA) with FIT test (Cologuard) during the MY or two (2) years prior. Fecal occult blood test (FOBT) during the MY. gFOBT (guaiac), FIT/iFOBT (immunochemical). Members 46–75 years as of ...